Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review

References

• Bachy E, Salles G. Treatment approach to newly diagnosed diffuse large B-cell lymphoma. Semin Hematol. 2015;52:107–118.
   PubMed Web of Science ®Google Scholar
• Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Roschewski M, Wilson WH. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. Clin Cancer Res. 2014;20:5182–5193.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Non-Hodgkin’s lymphoma: diagnosis and management NICE guideline [NG52]. 2016 [cited 2016 21 Nov]. https://www.nice.org.uk/guidance/NG52.
   Google Scholar
• National Institute for Health and Care Excellence. Checklist for prognostic studies. 2012 [cited 2016 11 Jan]. https://www.nice.org.uk/article/pmg6b/chapter/appendix-i-methodology-checklist-prognostic-studies.
   Google Scholar
• Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144:427–437.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96:1888–1890.
   PubMed Web of Science ®Google Scholar
• Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118:4173–4183.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Crouch S, Care MA, et al. Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol. 2012;159:441–453.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Beltran BE, Song MK, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36:413–417.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuilliere-Dartigues P, Baia M, et al. MYC gene simple hit is a strong independent predictive factor of survival in diffuse large b-cell lymphomas in contrast to MYC double-hit gene alterations: a study by the groupe d'etude des lymphomes de l'adulte. Blood. 2012;120:541.
   Google Scholar
• Coutinho R, Clear AJ, Owen A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013;19:6686–6695.
   PubMed Web of Science ®Google Scholar
• Culpin RE, Sieniawski M, Angus B, et al. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology. 2013;63:788–801.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1814–1826.
   Web of Science ®Google Scholar
• Dybkaer K, Bogsted M, Falgreen S, et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol. 2015;33:1379–1388.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91:705–714.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253–2263.
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Barth TFE, etet al. The prognostic impact of gene rearrangements and protein expression of MYC, BCL2 and BCL6 in young high-risk patients with DLBCL. Blood 2013;122:4262.
   Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021–4031.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121:2715–2724.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Park CS, Yoon DH, et al. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38:1046–1057.
   PubMed Web of Science ®Google Scholar
• Jardin F, Mareschal S, Figeac M, etet al. Integrated analysis of high-resolution gene expression and copy number profiling identified biallelic deletion of CDKN2A/2B tumor suppressor locus as the most frequent and unique genomic abnormality in diffuse large B-Cell Lymphoma (DLBCL) with strong prognostic value in both GCB and ABC subtypes and not overcome by a dose-intensive immunochemotherapy regimen plus rituximab. Results of a prospective GELA clinical trial program. Blood. 2012;120:415.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Kim YR, Kim SJ, Cheong JW, et al. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Ann Hematol. 2014;93:1867–1877.
   PubMed Web of Science ®Google Scholar
• Kojima M, Nishikii H, Takizawa J, et al. MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2149–2154.
   PubMed Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol. 2012;88:510–517.
   PubMed Web of Science ®Google Scholar
• Lopez AB, de Villambrosia SG, Montes-Moreno S, etet al. Prognostic value of cMYC gene abnormalities in diffuse large B cell lymphoma treated with chemo-immunotherapy. Blood. 2011;118:2664.
   Web of Science ®Google Scholar
• Madadi A, Raghavendra M, Hu S, etet al. Prognostic significance and phenotypic manifestations of MYC/BCL2 protein expression in diffuse large B-cell lymphoma (DLBCL) with extranodal organ involvement: a report of the international DLBCL rituximab-chop consortium program study. Blood. 2012;120:544.
   Web of Science ®Google Scholar
• Maeshima AM, Taniguchi H, Fukuhara S, et al. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci. 2012;103:1898–1904.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Iqbal J, Fu K, et al. CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. Br J Haematol. 2013;162:87–92.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi K, Masuda A, Wang Y-H, et al. Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. Int J Hematol. 2014;100:88–95.
   PubMed Web of Science ®Google Scholar
• Molina TJ, Briere J, Copie-Bergman C, etet al. Expression of MYC, IgM, as well as non-germinal centre B-cell like immunophenotype and positive immunofish index predict a worse progression free survival and overall survival in a series of 670 de novo diffuse large B-cell lymphomas included in clinical trials: a GELA study of the 2003 program. Blood. 2012;120:1539.
   PubMed Web of Science ®Google Scholar
• Molina TJ, Briere J, Copie-Bergman C, etet al. Overexpression of MYC, BCL2, MYC/BCL2, IgM, and nongerminal centre B cell-like immunophenotype predicts a worse progression-free survival and overall survival in a series of 670 de novo diffuse large B-cell lymphomas: S LYSA study. Hematol Oncol. 2013;31:156.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Martinez N, Sanchez-Espiridion B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118:1034–1040.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Batlle A, de Villambrosia SG, etet al. Risk adapted-high dose therapies modulate the impact of biological classification in diffuse large B cell lymphoma prognosis. Analysis of biological markers in patients from clinical trials in geltamo and gotel Spanish collaborative groups. Blood. 2012;120:2672.
   Web of Science ®Google Scholar
• Oh EJ, Yang WI, Cheong JW, et al. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression. Hum Pathol. 2014;45:2043–2050.
   PubMed Web of Science ®Google Scholar
• Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116:4916–4925.
   PubMed Web of Science ®Google Scholar
• Perry AM, Cardesa-Salzmann TM, Meyer PN, et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2012;120:2290–2296.
   PubMed Web of Science ®Google Scholar
• Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165:382–391.
   PubMed Web of Science ®Google Scholar
• Ruminy P, Mareschal S, Bagacean C, etet al. Accurate classification of GCB/ABC and MYC/BCL2 diffuse large B-cell lymphoma with a 14 genes expression signature and a simple and robust RT-MLPA assay. Blood. 2013;122:84.
   Web of Science ®Google Scholar
• Salles G, de JD, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–7078.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, etet al. Cell-of-origin assignment in diffuse large B-cell lymphoma determined by gene expression in formalin-fixed paraffin-embedded tissue has prognostic significance independent of ipi and MYC/BCL2 immunohistochemistry. Blood. 2014;124:06.
   Web of Science ®Google Scholar
• Trinh DL, Scott DW, Morin RD. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121:3666–3674.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27:958–971.
   PubMed Web of Science ®Google Scholar
• Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98:1554–1562.
   PubMed Web of Science ®Google Scholar
• Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26:2103–2113.
   PubMed Web of Science ®Google Scholar
• Wong KK, Gascoyne DM, Brown PJ, et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia. 2014;28:362–372.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986–3996.
   PubMed Web of Science ®Google Scholar
• Yan L-X, Liu Y-H, Luo D-L, et al. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One. 2014;9:e104068.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xiao L, Zhu X, et al. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China]. [Chinese]. Chung-Hua Ping Li Hsueh Tsa Chih – Chin J Pathol. 2014;43:383–388.
   Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
   PubMed Web of Science ®Google Scholar
• Veldman-Jones MH, Lai Z, Wappett M, et al. Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter System. Clin Cancer Res. 2015;21:2367–2378.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901.
   PubMed Web of Science ®Google Scholar
• Menter T, Medani H, Ahmad R, et al. MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas – presentation of a work-flow and the experience with 248 cases. Br J Haematol. 2016. [Epub ahead of print]. doi: 10.1111/bjh.14250
   Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal Gene Signatures in Large-B-Cell Lymphomas. N Engl J Med. 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011;17:7785–7795.
   PubMed Web of Science ®Google Scholar